title: Defensive and pathological functions of the gastrointestinal NK3 receptor.
abstract: In general, normal gut functions are unaffected by selective NK(3) receptor antagonists such as talnetant (SB-223412), osanetant (SR 142901) or SB-235375. However, NK(3) receptors may mediate certain defensive or pathological intestinal processes. The precise mechanisms, by which this role is achieved, are not fully understood. In summary, intense stimulation of the intrinsic primary afferent neurones (IPANs) of the enteric nervous system is thought to release tachykinins from these neurones, to induce slow excitation (slow EPSPs) of connecting IPANs. This is hypothesised to cause hypersensitivity and disrupt intestinal motility, at least partly explaining why NK(3) receptor antagonism can reduce the level of disruption caused by supramaximal distension pressures in vitro. Tachykinin release from IPANs may also increase C-fibre sensitivity, directly or indirectly. Thus, NK(3) receptor antagonists can inhibit nociception associated with intestinal distension, in normal animals or after pre-sensitisation by restraint stress. Importantly, such inhibition has been found with SB-235375, a peripherally restricted antagonist. SB-235375 can also reduce a visceromotor response to brief colorectal distension without affecting similar responses to skin pinch, providing additional evidence for intestinal-specific activity. NK(3) receptor biology is, therefore, revealing a novel pathway by which disruptions in intestinal motility and nociception can be induced.
authors.affiliation: GlaxoSmithKline, Harlow, Essex, UK. Gareth_J_Sanger@gsk.com
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Sanger
authors.forename: Bishwa R
authors.initials: BR
authors.lastname: Tuladhar
authors.forename: Lionel
authors.initials: L
authors.lastname: Bueno
authors.forename: John B
authors.initials: JB
authors.lastname: Furness
mesh_terms: D015746:Abdominal Pain / Q000503:physiopathology / Q000517:prevention & control; D000085:Acetates / Q000494:pharmacology; D000818:Animals; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D010880:Piperidines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors / Q000502:physiology*; D015320:Tachykinins / Q000378:metabolism
chemical_list: D000085:Acetates; C444647:N-(alpha-ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide; D010880:Piperidines; D011804:Quinolines; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; C106716:SB 223412; C091554:SR 142801